To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Summary

JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II open-label, single-arm study aims to evaluate the efficacy and safety of JS002 in patients with homozygous familial hypercholesterolemia A dose group (450 mg) was set up in this study.Thirty subjects are planned to be enrolled. Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks of follow-up.

Timeline

Start

2020-08-17

Primary completion

2022-05-06

Completion

2022-07-29

Drugs

Indications